the national optimal lung cancer pathway · performance status at presentation. wide variation in...
TRANSCRIPT
![Page 1: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/1.jpg)
The National Optimal Lung Cancer Pathway
Sadia Anwar
![Page 2: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/2.jpg)
Overview●State of lung cancer●NOLCP - pathways●Rationale/ evidence● Implementation NUH●Primary care
![Page 3: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/3.jpg)
Incidence of common cancers UK, 2014
CRUK
![Page 4: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/4.jpg)
CRUK
Mortality from common cancers UK, 2014
![Page 5: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/5.jpg)
1 year Survival E&W 2010-2011
CRUK
![Page 6: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/6.jpg)
Coleman et al Lancet 2011; 377: 127–38
CAN
SWE
NOR
DEN
UK
AUS
CAN
SWENORDEN
UK
AUS
ICBP: International comparison of relative survival
![Page 7: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/7.jpg)
ICBP: Comparison of stage distribution
Country n= Stage 1 %
Stage 2 %
Stage 3 % Stage 4% missing
data
Canada 8648 20 5 26.4 48.6 5.6
Denmark 13681 14.4 5.8 24.9 55 11.2
Sweden 4570 19.7 3.5 29.9 47 5.8
UK 22993 14.8 7.3 29.5 48.4 30.3
Walters et al 2013
![Page 8: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/8.jpg)
Performance status at presentation
![Page 9: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/9.jpg)
wide variation in access to diagnostics and treatment
variation in pathways, treatment rates, outcomes not explained by case mix
Unwarranted variation
![Page 10: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/10.jpg)
![Page 11: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/11.jpg)
Surgery for Non- small cell
0
0.4
0.8
1.1
1.5
Non surgical centre or unit
Chemotherapy for small cell
0
0.4
0.8
1.1
1.5
<5% chemo trials >5% chemo trials
Adj
uste
d O
dds
Rat
io
Rich AL et al British Journal Of Cancer.2011;105(6):746-52Rich A L et al Thorax. 66(12), 1078-84
42%51%
NHS Trust first contact: adjusted OR
![Page 12: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/12.jpg)
● ICT aim: reduce emergency admission diagnoses● 35% lung cancers diagnosed as EA● short survival
● EM audit: most had primary care contact in preceding weeks; 50% of EA diagnosed referred in by primary care
● CADIAS study
Emergency presentation
![Page 13: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/13.jpg)
32
4542
13
Emergency GP / 2 WWOther OP Other IP
NCIN 2015
Routes to diagnosis: 1 year survival (%)
![Page 14: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/14.jpg)
Problems
• late diagnosis
• poor PS/ co morbidities
• unwarranted variations in care
• treatment
![Page 15: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/15.jpg)
National Optimal Lung Cancer Pathway
● CEG for lung cancer, NHSE●Whole of pathway commissioning guidance●National pathway requested by NHSE clinical
panel●Wide consultation● Jan 2016 v1●Aug 2017 v2
![Page 16: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/16.jpg)
●Accelerate, standardise and optimise care
● Improve patient outcomes●Reduce unwarranted variation●Reduce emergency admission presentation●Achieve national performance targets
Objectives
![Page 17: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/17.jpg)
Pathways developed
●Optimal pathway ●Straight to CT●Triage●Curative intent●Direct to biopsy
![Page 18: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/18.jpg)
National Optimal Lung Cancer Pathway
Throughout pathway consider: Supportive and palliative care Smoking cessation Research trials Optimise PS Full MDT discussion of treatment options
Day 1-6
Day 28
Day 33
Day 49
Suitable for potentially curative treatment?+
Fast track lung cancer clinic. Meet LCNS. Diagnostic process plan / diagnostic planning meeting prior to
clinic Treatment of co-morbidity and palliation / treatment of
symptoms
Curative Intent Management pathway*(4)
Test bundle requested at first OPA including at least: PET-CT and as
required: detailed lung function and cardiac assessment / ECHO.
Meet with LCNS and receive information.
Day 0-3
No
No cancer: Manage/discharge
Day 42
Lung cancer unlikely Further management according to
local protocol with options of further management of CT findings by primary care or
secondary care (see separate detailed algorithm)
CT within 24 hours if clinically indicated; inpatients seen within 48 hours by acute oncology, respiratory and/or
palliative services
Yes
Surgery Specialist palliative care
Chemotherapy Radiotherapy
First Treatment
Other palliative
treatments
TRIAGE*(1,2) (by radiology or respiratory medicine according to local protocol) Lung cancer suspected?
Investigations to yield maximum diagnostic AND staging information with least harm. Results available within 3
days for subtype and 10 days for molecular markers.
GP
CT abnormal?
CXR suspicious of lung cancer? (reported before patient leaves dept. or within 24
hours.)
No
Yes
Yes
No
Yes No
Yes
Maximum times
Maximum times
High clinical suspicion?
No
Yes
Urgent or routine CXR
CT same day / within 72 hours
Further investigation(s)?
Follow-up Lung Cancer Clinic Cancer Confirmed and treatment options
discussed. Research trial considered. LCNS present
OPA with treating specialist (within 3 working days)
Further investigation(s)?
No
Yes
No
Yes
Clinical diagnosis or patient preference means biopsy not
required.
Will pathological diagnosis influence treatment and is potential treatment appropriate to patient’s wishes?
Day 21
Direct referral criteria (N
ICE)
No
Further investigation(s) indicated?
No
Yes
CT suspicious of lung cancer?
NoYes Manage
CT n
ot in
dica
ted
Hospitals referrals (A&E, internal or incidental findings) for suspected lung cancer
NIC
E re
ferr
al
guid
ance
Day -3-0
Further discussion needed?
Yes
No
*Refer to separate numbered pathway detail
$ Some or all diagnosis and staging tests may be in a tertiary centre
+ Low threshold for curative intent pathway; may discuss with wider MDT if unsure
Direct biopsy option*(3)
Throughout pathway: • consider entry into a research trial • offer supportive &
palliative care, e.g. by LCNS, G
P, specialists in palliative care • encourage smoking cessation
![Page 19: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/19.jpg)
Early Pathway
![Page 20: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/20.jpg)
Full!MDT!discussion!of!treatment!options
Day!1-5
Suitable!for!potentially!curative!treatment?+!
Fast!track!lung!cancer!clinic.!Meet!LCNS.!Diagnost ic!process!plan!/ !diagnost ic!planning!meeting!prior!to!clinicTreatment !of!co-morbidity!and!palliat ion!/ !t reatment !of!symptoms!
Curative!Intent!Management!pathway*Test !bundle!requested!at !first !OPAincluding!at!least:!PET-CT!!and!as!required:!detailed!lung!funct ion!and!
cardiac!assessment ! / !ECHO.Meet !with!LCNS!and!receive!informat ion.!
Day!0-3!!
No!
Lung!cancer!unlikelyFurther!management!according!to!local protocol!with!options!of!
further!management!of!CT!findings!by!primary!care!or!secondary!care!(see!separate!detailed!algorithm)
Yes
TRIAGE!(by!radiology!or!respiratory!medicine!according!to!local!protocol)!Lung!cancer!suspected?
Invest igat ions!to!yield!maximum!diagnost ic!AND!staging!informat ion!with!least !harm.!Results!available!within!3!days!for!subtype!
and!10!days!for!molecular!markers.
Yes No
Yes
Clinical!diagnosisor!pat ient !preference!means!biopsy!not !
required.!!
Will!pathological!diagnosis!influence! t reatment and!is!potent ial!t reatment !appropriate!to!pat ient ’s!wishes?
Day!21
No!
Further! investigation(s)!indicated?
No!
Yes
Direct!biopsy!option*
Mid Pathway
![Page 21: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/21.jpg)
Triage
Lung cancer pathway
Fast track lung cancer clinic. Meet LCNS.
Diagnostic process plan / diagnostic planning meeting prior to clinic.Treatment of co-morbidity and
palliation / treatment of symptoms.
Non urgent condition?
No
Yes No
Manage in primary care or non urgent referral.
Management of pulmonary nodules is included here.
GP manages patient
TRIAGE By radiologist or chest physician CT + clinical info
Lung cancer likely?Yes
Condition requiring urgent appointment including other cancer?
No
Non lung cancer pathway
Yes
Refer for urgent clinic, admission or other fast track
cancer referral
![Page 22: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/22.jpg)
Usual diagnosis and staging
pathway
Stage: Potentially T1-3 N0-2 M0 (N2 non-bulky; i.e. <3cm)Or locally advanced; potential for radical RT?
May include selected patients with oligometastatic disease
Full MDT Discussion of treatment options or further investigation
No
Fast track lung cancer clinic ± diagnostic planning meeting / Diagnostic MDT
Meet lung cancer nurse specialist
Patients with borderline fitness$ add:• Preoperative rehabilitation• Shuttle walk test / CPEX / ECHO• Perfusion scan if required• Early cardiology assessment for
cardiac co-morbidity
Simultaneous fast track:
Yes
All patients:• Medical optimisation (incl. smoking cessation)• PET-CT (within 5 days)• Diagnostic and staging tests• Spirometry ±TLCO• Complete all tests within 14 days• Alert surgeons / clinical oncology
Potentially fit enough for treatment with curative intent and willing to consider this? (Ensure low threshold for proceeding with
work up for curative treatment)
No
Yes
Day 1-5
Maximum times
NOLCP
Day 21
National Optimal Curative Intent Management Pathway
![Page 23: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/23.jpg)
Mid pathway
![Page 24: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/24.jpg)
First treatment pathway
![Page 25: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/25.jpg)
Requirements
●Straight to CT●Test bundles●Rapid turnaround times●Protocols●Flexibility of scheduling ●Capacity
![Page 26: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/26.jpg)
● Comply with current and future CWT ● 62d nationally 75% v 85%● NHS Cancer plan 2000● Independent Cancer Taskforce:- diagnosis 50% by 2 weeks, 95% by 4 weeks
● Patient anxiety and experience (nb speed v quality)
● Evidence that faster pathways result in better outcomes-RCT and non RCT
Rationale: speed
![Page 27: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/27.jpg)
Navani N, et al. Lancet Respiratory Medicine 2015;3(4):282–289
EBUS as first test v conventional: overall survival
![Page 28: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/28.jpg)
Triage
● retrospective comparative cohort study● reduced time to diagnosis● reduced time to treatment● increased patient satisfaction
![Page 29: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/29.jpg)
● Shorter time to diagnosis lengthens survival ● lead time may improve treatment options if PS
more favourable● 26% patients report health decline awaiting OPA● PS very strongly correlated with● Prognosis● Access to treatment (all modalities)● Response to treatment
Rationale: PS
![Page 30: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/30.jpg)
PS and mortality from surgeryPS Alive at 90 d Dead at 90 d Adj. OR* 95% CI
0 3422 (31.1) 132 (3.9) 1.00
1 2815 (25.6) 177 (6.3) 1.38 1.09 to 1.75
2 465 (4.2) 51 (11.0) 2.40 1.68 to 3.41
3–4 108 (1.0) 20 (18.5) 4.08 2.37 to 7.02
Missing 4181 (38.0) 267 (6.4 ) 1.35 1.06 to 1.73
* Adjusted for age, sex, ethnicity, deprivation, comorbidity, FEV1, stage, laterality, histology and procedure type.
Powell HA et al Thorax 2013;68:826-834
PS and age strongly influence mortalityAppropriate patient selection is key
![Page 31: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/31.jpg)
Chest x-rays prior to a diagnosis of lung cancer in general practice
Barbara Iyen-Omofoman et al. Thorax 2013;68:451-459
![Page 32: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/32.jpg)
● Cost effectiveness - reporting radiographers; - reduced interspecialty handover- reduced repeat scans and bx
● Stratified management● avoid delays in complex pathways● divert those without cancer appropriately
Rationale
![Page 33: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/33.jpg)
● Formal project structure- 5 workstreams (admin, tertiary, referral,
diagnostic, treatment) ● Bids for Alliance Transformation funding● Cross discipline and boundary engagement ● Themes from RCAs for breaches (multiple)
● Organisational● Demand/ capacity
Local implementation: NUH progress
![Page 34: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/34.jpg)
● Triage - 1/3 off pathway● CXR to CT pathway -
CCGs, GPs, rad, resp● Same day US neck bx● Ambulatory lung bx● ACE programme: direct to
CT for normal CXR● Chest physician
recruitment● OP clinic management - in
house
Local implementation: NUH progress
● Endoscopy● Pathology - transport,
test sequences, lab staff, business case
● Oncology: ACPs● LCNS recruitment● Surgery: clinic
scheduling, admin
![Page 35: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/35.jpg)
● Advocacy:● Evidence based, guideline driven● Supported by CRUK, NHSE, Alliances, QA, RCF
● Cross specialty and cross boundary● Data quality● Resources● Cancer Alliances support ICT strategy● £160 million cancer transformation funds from
NHSE to support taskforce recommendations
Challenges
![Page 36: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/36.jpg)
Shared learning
●Liverpool Heart and Chest: streamlined pathway●Homerton reporting radiographers●Leicester diagnostic MDT arrangements●Kettering ambulatory care service●Royal Free London ambulatory lung biopsy●South Tyneside one stop clinic●S Manchester - RAPID programme
![Page 37: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/37.jpg)
Systematic and radical change Multi faceted problem needs a multi faceted approach
![Page 38: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/38.jpg)
●Recognition
●Risk assessment
●Tests: CXR
●Referral
●?screening
Early diagnosis: the GP role
![Page 39: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/39.jpg)
● 1.1.1 Refer people using a suspected cancer pathway referral (for an appointment within 2 weeks) for lung cancer if they:
● have chest X-ray findings that suggest lung cancer or
● are aged 40 and over with unexplained haemoptysis. [new 2015]
Suspected cancer: Recognition and Referral, NICE NG12, 2015
![Page 40: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/40.jpg)
● 1.1.2 Offer an urgent chest X-ray in people aged ≥40 if they:
● have 2 or more of the following unexplained symptoms ● have ever smoked and have 1 or more of the following
unexplained symptoms:
● cough ● fatigue ● shortness of breath ● chest pain ● weight loss ● appetite loss. [new 2015]
● nb CXR - new COPD or heart failure
NICE NG12
![Page 41: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/41.jpg)
● Estimated 700 additional cancers diagnosed, compared to the same period in the previous year.
● Approximately 400 more people diagnosed at an earlier stage (23.4% to 26.1%)
● Around 300 additional patients had surgery (13.6% to 16%)
Be Clear on Cancer evaluation update 2014
Be Clear on Cancer Campaign May to July 2012
![Page 42: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/42.jpg)
● 1.1.3 Consider an urgent chest X-ray to assess for lung cancer in people aged ≥40 with any of the following:
● persistent or recurrent chest infection ● finger clubbing ● supraclavicular lymphadenopathy or persistent
cervical lymphadenopathy ● chest signs consistent with lung cancer ● thrombocytosis. [new 2015]
● nb CXR v low risk radiation
NICE NG12
![Page 43: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/43.jpg)
● 1.15.1 …… Be aware of the possibility of false-negative results for chest X-rays …. [new 2015]
● 1.15.2 Consider a review for people with any symptom that is associated with an increased risk of cancer, but who do not meet the criteria for referral or other investigative action.
● nb ● Can be appropriate to refer with normal CXR
NICE NG12: Safety netting
![Page 44: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/44.jpg)
Risk assessment●biggest risk factors:●age●smoking status
●Decision support tools:●Q cancer●RAT●Others
●All have limitations●All adjuncts to GP assessment●Should not stop you referring
● symptoms - major? unexplained? refractory?
● CXR
● Refer or direct to CT if CXR normal and still high risk
![Page 45: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/45.jpg)
Thank you
![Page 46: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/46.jpg)
GP Direct to CT?
Persistent (>3 weeks) Dyspnoea or cough Resolved minor haemoptysis High risk of lung cancer Unexplained change in symptoms in patients with chronic respiratory disease
CT Request by GP
CT report to GP; If cancer direct to 2WW
Normal
Conventional route
CXR
GP 2WW referral
Patient presents to GP
Consider NICE referral criteria (including risk factors)
Other diagnosis Suggestive of Lung cancer
![Page 47: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/47.jpg)
● Low dose CT screening in high risk groups ● Awaiting Health Technology Assessment
Review and ● The UK National Screening make the
recommendation ● ?age 55-80, 3% risk, annual screen
The future
![Page 48: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/48.jpg)
CADIAS Study & SEA Audit
48
![Page 49: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/49.jpg)
Standardised CXR rates by PracticeAg
e an
d se
x-st
anda
rdis
ed C
XR r
ates
per
100
po
pula
tion
0
4.5
9
13.5
18
Practice
Median 3.8/100 population (IQR 2.7-5.3)
Emma L O’Dowd, Trica M McEveer, David R Baldwin et al Thorax 2015;70:161-168
![Page 50: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/50.jpg)
Practice CXR requests and outcomes
Died within 90 days 95% CI
OR
CXR quartile 1-2.73/100 patients 1
2.74-3.84/100 patients 1.03 0.94-1.14
3.85-5.33/100 patients 1.28 1.16-1.41
≥5.34/100 patients 1.41 1.29-1.55
• Possible ascertainment bias in the higher quartiles
Emma L O’Dowd, Trica M McEveer, David R Baldwin et al Thorax 2015;70:161-168
![Page 51: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/51.jpg)
Lung Cancer symptoms at referral
No malignant Percent No benign Percent
No patients 650 392Cough 266 41 255 65Dyspnoea 355 55 153 39Weight loss 308 47 100 26Haemoptysis 140 22 119 30Chest pain 256 39 80 20
Lewis NR, Le Jeune I, Baldwin DR. British Journal of Cancer (2005) 93, 905–908.
![Page 52: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/52.jpg)
SYMPTOM Study
Walter FM, Rubin G, Bankhead C, Morris HC, Hall N, Mills K, et al. Br J Cancer. 2015;112 Suppl 1:S6-13.
![Page 53: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/53.jpg)
PPVs for lung cancer for individual risk markers and for pairs of risk markers in combination
W Hamilton et al. Thorax 2005;60:1059-1065
![Page 54: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/54.jpg)
QCancer
Hippisley-Cox J and Coupland C. Br J Gen Pract 2011; DOI: 10.3399/bjgp11X606627
![Page 55: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/55.jpg)
Quantifying risk
First author Database Cases Dates Setting
Hamilton 2005 Notes review 247 1998-2002 Exeter practices
Jones 2007 GPRD (224) 1994-2000 National
Hippisley-Cox 2011 EMIS /Qresearch
3785 2000-2010 National
Iyen-Omofoman 2013 THIN 12074 2000-2009 National
![Page 56: The National Optimal Lung Cancer Pathway · Performance status at presentation. wide variation in access to diagnostics and treatment variation in pathways, treatment rates, outcomes](https://reader034.vdocument.in/reader034/viewer/2022050311/5f72ba3b85dcb5322b79d764/html5/thumbnails/56.jpg)
Proposal – comparison of methods within ACE projects
CXR
GP Fast track referral
Patient presents to GP
Other diagnosis Suggestive of Lung cancer
NICE referral criteria
Macmillan tool
Qcancer risk 3%
Iyen-O risk 3%
New criteria
Manage on basis of the score tool with the highest risk / referral criteria met
?CT
Evaluate: Number of cancers Number referrals without cancer Number of cancers missed by each score Stage Number of emergency admissions